Pfizer May Be Regaining Appetite For Large M&A; Is Bristol On The Menu?
Executive Summary
Pfizer appears to be more open to large-scale mergers and acquisitions than it has been in recent years, comments by Vice Chairman David Shedlarz suggest
You may also be interested in...
Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist
The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm
Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist
The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm
Pfizer Cost-Cutting: Details Are Sketchy, But Sales Force Is On The Table
Pfizer CEO Jeffrey Kindler has opened the door to sales force reductions as part of the firm's latest cost-cutting initiative, announced Oct. 1